| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 23 | 2023 | 767 | 5.720 |
Why?
|
| Leukemia, Myeloid, Acute | 75 | 2024 | 6915 | 4.930 |
Why?
|
| Myelodysplastic Syndromes | 24 | 2024 | 2979 | 3.240 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 12 | 2023 | 426 | 2.800 |
Why?
|
| Bone Marrow | 24 | 2022 | 2358 | 2.420 |
Why?
|
| Hematologic Neoplasms | 15 | 2023 | 1870 | 2.260 |
Why?
|
| Mutation | 68 | 2023 | 15179 | 2.080 |
Why?
|
| Social Media | 4 | 2021 | 203 | 1.900 |
Why?
|
| Hematology | 3 | 2021 | 104 | 1.570 |
Why?
|
| Tumor Suppressor Protein p53 | 16 | 2023 | 3552 | 1.530 |
Why?
|
| Scholarly Communication | 2 | 2020 | 19 | 1.520 |
Why?
|
| Pathologists | 2 | 2020 | 91 | 1.450 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 12 | 2023 | 801 | 1.360 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 17 | 2024 | 923 | 1.310 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2021 | 489 | 1.280 |
Why?
|
| Calreticulin | 4 | 2016 | 74 | 1.230 |
Why?
|
| Humans | 197 | 2024 | 261506 | 1.190 |
Why?
|
| Immunophenotyping | 19 | 2023 | 1681 | 1.180 |
Why?
|
| Neoplasms | 14 | 2023 | 15193 | 1.100 |
Why?
|
| Nuclear Proteins | 10 | 2023 | 3343 | 1.100 |
Why?
|
| Chromosome Aberrations | 7 | 2023 | 1960 | 1.090 |
Why?
|
| Primary Myelofibrosis | 5 | 2022 | 831 | 1.080 |
Why?
|
| Lymphoma, B-Cell | 5 | 2024 | 895 | 1.050 |
Why?
|
| Dendritic Cells | 8 | 2022 | 1085 | 1.020 |
Why?
|
| Neoplasm Proteins | 7 | 2022 | 3230 | 0.990 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 | 2024 | 2390 | 0.980 |
Why?
|
| Plasmacytoma | 2 | 2015 | 111 | 0.980 |
Why?
|
| Isocitrate Dehydrogenase | 8 | 2023 | 480 | 0.980 |
Why?
|
| Aged | 88 | 2023 | 70117 | 0.930 |
Why?
|
| Middle Aged | 93 | 2023 | 86204 | 0.910 |
Why?
|
| Pathology | 2 | 2021 | 101 | 0.900 |
Why?
|
| Leukemia, Myeloid | 4 | 2021 | 941 | 0.890 |
Why?
|
| Fusion Proteins, bcr-abl | 7 | 2023 | 1094 | 0.870 |
Why?
|
| Leukemoid Reaction | 2 | 2020 | 12 | 0.870 |
Why?
|
| Hemoglobin SC Disease | 1 | 2022 | 13 | 0.860 |
Why?
|
| Thrombocythemia, Essential | 2 | 2022 | 162 | 0.860 |
Why?
|
| Priapism | 1 | 2022 | 10 | 0.860 |
Why?
|
| Aged, 80 and over | 48 | 2023 | 29902 | 0.830 |
Why?
|
| Dioxygenases | 3 | 2021 | 159 | 0.810 |
Why?
|
| Herpesvirus 4, Human | 3 | 2023 | 966 | 0.810 |
Why?
|
| Biomarkers, Tumor | 15 | 2020 | 10331 | 0.800 |
Why?
|
| WT1 Proteins | 1 | 2022 | 106 | 0.790 |
Why?
|
| Adult | 80 | 2024 | 77950 | 0.790 |
Why?
|
| Information Dissemination | 2 | 2020 | 272 | 0.770 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2021 | 49 | 0.770 |
Why?
|
| Education, Medical, Continuing | 2 | 2020 | 251 | 0.770 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 28 | 2023 | 15862 | 0.770 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2021 | 755 | 0.760 |
Why?
|
| Male | 93 | 2023 | 123000 | 0.750 |
Why?
|
| Attitude to Computers | 1 | 2020 | 71 | 0.740 |
Why?
|
| High-Throughput Nucleotide Sequencing | 11 | 2023 | 2291 | 0.730 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 242 | 0.730 |
Why?
|
| Sulfonamides | 17 | 2024 | 1823 | 0.720 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2018 | 132 | 0.720 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 5 | 2024 | 217 | 0.720 |
Why?
|
| B-Lymphocytes | 5 | 2021 | 1294 | 0.710 |
Why?
|
| Education, Medical | 2 | 2021 | 331 | 0.710 |
Why?
|
| Histiocytosis | 2 | 2022 | 54 | 0.710 |
Why?
|
| Prognosis | 40 | 2024 | 21713 | 0.710 |
Why?
|
| Skin Neoplasms | 9 | 2022 | 4654 | 0.710 |
Why?
|
| Plasmablastic Lymphoma | 2 | 2021 | 37 | 0.710 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 4 | 2023 | 197 | 0.700 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 130 | 0.700 |
Why?
|
| Megakaryocytes | 3 | 2016 | 104 | 0.690 |
Why?
|
| Eosinophilia | 2 | 2020 | 176 | 0.680 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 158 | 0.670 |
Why?
|
| Clonal Evolution | 5 | 2020 | 253 | 0.670 |
Why?
|
| World Health Organization | 5 | 2023 | 316 | 0.660 |
Why?
|
| Abnormal Karyotype | 1 | 2018 | 100 | 0.650 |
Why?
|
| Breast Implantation | 2 | 2019 | 228 | 0.650 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 339 | 0.650 |
Why?
|
| Female | 87 | 2023 | 141928 | 0.640 |
Why?
|
| Immunohistochemistry | 17 | 2023 | 7548 | 0.620 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2024 | 713 | 0.620 |
Why?
|
| Bone Marrow Cells | 3 | 2018 | 943 | 0.610 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 8 | 2023 | 1664 | 0.610 |
Why?
|
| Lymphoma | 2 | 2016 | 1467 | 0.600 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2019 | 387 | 0.590 |
Why?
|
| Young Adult | 36 | 2023 | 21445 | 0.570 |
Why?
|
| Breast Implants | 2 | 2019 | 391 | 0.570 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2022 | 6550 | 0.570 |
Why?
|
| Pathology Department, Hospital | 1 | 2016 | 14 | 0.570 |
Why?
|
| Translocation, Genetic | 8 | 2021 | 1245 | 0.570 |
Why?
|
| Germinal Center | 1 | 2017 | 161 | 0.570 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 3 | 2022 | 153 | 0.560 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2017 | 115 | 0.550 |
Why?
|
| Blast Crisis | 2 | 2018 | 557 | 0.550 |
Why?
|
| Azacitidine | 7 | 2023 | 1149 | 0.540 |
Why?
|
| Biopsy | 13 | 2019 | 3443 | 0.530 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2015 | 35 | 0.530 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2023 | 2527 | 0.530 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2015 | 310 | 0.530 |
Why?
|
| Disease-Free Survival | 19 | 2023 | 10001 | 0.510 |
Why?
|
| Standard of Care | 1 | 2016 | 243 | 0.500 |
Why?
|
| Flow Cytometry | 9 | 2023 | 3033 | 0.500 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 3 | 2022 | 114 | 0.500 |
Why?
|
| Mesothelioma | 1 | 2020 | 544 | 0.500 |
Why?
|
| Lymph Nodes | 8 | 2020 | 2967 | 0.500 |
Why?
|
| Remission Induction | 14 | 2023 | 3569 | 0.490 |
Why?
|
| Skin Diseases | 1 | 2017 | 349 | 0.490 |
Why?
|
| Nevus, Blue | 1 | 2014 | 40 | 0.480 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2017 | 261 | 0.470 |
Why?
|
| Positron-Emission Tomography | 3 | 2017 | 2173 | 0.470 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 2796 | 0.470 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2024 | 1242 | 0.470 |
Why?
|
| Janus Kinase 2 | 6 | 2022 | 679 | 0.460 |
Why?
|
| Neoplasm, Residual | 10 | 2023 | 1656 | 0.450 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 821 | 0.450 |
Why?
|
| Lymphoma, T-Cell | 1 | 2016 | 361 | 0.440 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 1209 | 0.440 |
Why?
|
| Nose Neoplasms | 1 | 2015 | 229 | 0.430 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2021 | 305 | 0.430 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2017 | 1283 | 0.430 |
Why?
|
| Aging | 1 | 2021 | 1582 | 0.420 |
Why?
|
| Breast | 2 | 2018 | 1344 | 0.420 |
Why?
|
| Internship and Residency | 1 | 2023 | 1375 | 0.420 |
Why?
|
| Tandem Repeat Sequences | 4 | 2020 | 201 | 0.410 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 1217 | 0.410 |
Why?
|
| Biomarkers | 11 | 2022 | 5047 | 0.410 |
Why?
|
| Papanicolaou Test | 1 | 2012 | 141 | 0.400 |
Why?
|
| Mutation, Missense | 1 | 2017 | 1152 | 0.400 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 2195 | 0.400 |
Why?
|
| Vaginal Smears | 1 | 2012 | 192 | 0.390 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2017 | 1039 | 0.390 |
Why?
|
| Mediastinal Neoplasms | 1 | 2015 | 423 | 0.390 |
Why?
|
| Blood Platelet Disorders | 2 | 2024 | 37 | 0.380 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 4821 | 0.380 |
Why?
|
| Thiazoles | 1 | 2015 | 726 | 0.380 |
Why?
|
| Triage | 1 | 2012 | 252 | 0.370 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2012 | 219 | 0.370 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2023 | 4757 | 0.370 |
Why?
|
| Disease Management | 6 | 2021 | 1052 | 0.370 |
Why?
|
| Cytarabine | 8 | 2023 | 1973 | 0.370 |
Why?
|
| Hemangioma | 1 | 2011 | 154 | 0.360 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2024 | 1331 | 0.360 |
Why?
|
| DNA Mutational Analysis | 9 | 2020 | 2283 | 0.350 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 3 | 2020 | 63 | 0.350 |
Why?
|
| Germ-Line Mutation | 3 | 2020 | 1046 | 0.350 |
Why?
|
| Polyomavirus Infections | 1 | 2010 | 139 | 0.350 |
Why?
|
| Histiocytosis, Sinus | 2 | 2020 | 86 | 0.340 |
Why?
|
| Heart Neoplasms | 1 | 2011 | 214 | 0.340 |
Why?
|
| Cell Proliferation | 2 | 2018 | 7226 | 0.330 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2023 | 461 | 0.330 |
Why?
|
| Gene Rearrangement | 3 | 2022 | 783 | 0.330 |
Why?
|
| Pyrimidines | 3 | 2016 | 3518 | 0.320 |
Why?
|
| Serine-Arginine Splicing Factors | 3 | 2023 | 88 | 0.320 |
Why?
|
| Recurrence | 9 | 2023 | 4758 | 0.320 |
Why?
|
| Imatinib Mesylate | 3 | 2022 | 1665 | 0.320 |
Why?
|
| Core Binding Factor beta Subunit | 2 | 2019 | 46 | 0.320 |
Why?
|
| Cytogenetic Analysis | 6 | 2023 | 568 | 0.310 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2021 | 2359 | 0.310 |
Why?
|
| Waldenstrom Macroglobulinemia | 3 | 2016 | 273 | 0.310 |
Why?
|
| Leukemia | 3 | 2022 | 1635 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2020 | 311 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 10035 | 0.310 |
Why?
|
| Neoplasms, Second Primary | 4 | 2021 | 1350 | 0.310 |
Why?
|
| Survival Rate | 13 | 2022 | 12221 | 0.300 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 482 | 0.290 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2020 | 2232 | 0.290 |
Why?
|
| Ovary | 2 | 2020 | 668 | 0.280 |
Why?
|
| Age Factors | 4 | 2021 | 5377 | 0.270 |
Why?
|
| Alleles | 4 | 2020 | 2437 | 0.270 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2017 | 166 | 0.270 |
Why?
|
| Repressor Proteins | 3 | 2024 | 1664 | 0.270 |
Why?
|
| Time Factors | 9 | 2020 | 12926 | 0.270 |
Why?
|
| Disease Progression | 8 | 2021 | 6682 | 0.270 |
Why?
|
| Idarubicin | 3 | 2022 | 446 | 0.260 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2024 | 1823 | 0.250 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2021 | 5539 | 0.250 |
Why?
|
| Karyotype | 3 | 2019 | 234 | 0.250 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 2576 | 0.240 |
Why?
|
| Treatment Outcome | 20 | 2023 | 32848 | 0.240 |
Why?
|
| Trees | 1 | 2023 | 15 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2024 | 1493 | 0.240 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 4053 | 0.240 |
Why?
|
| Retrospective Studies | 24 | 2024 | 37905 | 0.240 |
Why?
|
| Rituximab | 4 | 2019 | 1528 | 0.230 |
Why?
|
| Receptor, Notch1 | 2 | 2022 | 218 | 0.230 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2010 | 962 | 0.230 |
Why?
|
| Risk Assessment | 7 | 2023 | 6869 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2021 | 6207 | 0.220 |
Why?
|
| RNA, Viral | 2 | 2016 | 671 | 0.220 |
Why?
|
| Acute Disease | 3 | 2024 | 2422 | 0.220 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2020 | 155 | 0.200 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2021 | 41 | 0.200 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2022 | 118 | 0.200 |
Why?
|
| Doxorubicin | 4 | 2023 | 3005 | 0.200 |
Why?
|
| Genomics | 6 | 2024 | 2738 | 0.200 |
Why?
|
| Hodgkin Disease | 2 | 2022 | 1429 | 0.200 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2023 | 255 | 0.200 |
Why?
|
| Induction Chemotherapy | 2 | 2022 | 669 | 0.200 |
Why?
|
| Adolescent | 15 | 2022 | 31252 | 0.200 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 1833 | 0.200 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2022 | 113 | 0.200 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 3168 | 0.200 |
Why?
|
| Triazines | 1 | 2022 | 117 | 0.200 |
Why?
|
| Melanoma | 2 | 2018 | 5317 | 0.190 |
Why?
|
| Phenotype | 7 | 2023 | 6295 | 0.190 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 538 | 0.190 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2020 | 9 | 0.190 |
Why?
|
| Arsenicals | 1 | 2021 | 201 | 0.190 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2022 | 245 | 0.190 |
Why?
|
| Pyridazines | 1 | 2023 | 293 | 0.190 |
Why?
|
| Videoconferencing | 1 | 2020 | 56 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2021 | 125 | 0.190 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 4892 | 0.190 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2021 | 118 | 0.190 |
Why?
|
| Bone Marrow Examination | 2 | 2018 | 153 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2023 | 5178 | 0.190 |
Why?
|
| T-Lymphocytes | 3 | 2018 | 3869 | 0.180 |
Why?
|
| Antineoplastic Agents | 7 | 2023 | 14289 | 0.180 |
Why?
|
| Education, Distance | 1 | 2021 | 93 | 0.180 |
Why?
|
| Sweet Syndrome | 1 | 2020 | 36 | 0.180 |
Why?
|
| Aminopyridines | 1 | 2022 | 212 | 0.180 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2020 | 58 | 0.180 |
Why?
|
| Multiple Myeloma | 2 | 2021 | 2138 | 0.180 |
Why?
|
| CREB-Binding Protein | 1 | 2020 | 86 | 0.180 |
Why?
|
| Transcription Factor 4 | 1 | 2019 | 36 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2020 | 185 | 0.180 |
Why?
|
| Philadelphia Chromosome | 3 | 2023 | 793 | 0.180 |
Why?
|
| Gene Frequency | 2 | 2021 | 1163 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2020 | 234 | 0.180 |
Why?
|
| Reticulin | 2 | 2018 | 22 | 0.180 |
Why?
|
| Specialization | 1 | 2020 | 130 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 246 | 0.170 |
Why?
|
| Myeloid Cells | 1 | 2021 | 269 | 0.170 |
Why?
|
| In Situ Hybridization | 3 | 2017 | 1037 | 0.170 |
Why?
|
| Genotype | 3 | 2016 | 4109 | 0.170 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2019 | 83 | 0.170 |
Why?
|
| Inflammasomes | 1 | 2021 | 161 | 0.170 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2019 | 106 | 0.170 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2019 | 52 | 0.170 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 1022 | 0.170 |
Why?
|
| Congresses as Topic | 1 | 2020 | 298 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2020 | 254 | 0.160 |
Why?
|
| Ilium | 1 | 2018 | 54 | 0.160 |
Why?
|
| Amino Acid Substitution | 2 | 2017 | 644 | 0.160 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2021 | 430 | 0.160 |
Why?
|
| Chronic Disease | 2 | 2021 | 1819 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2020 | 402 | 0.160 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 475 | 0.160 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2018 | 89 | 0.160 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 4744 | 0.160 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 4988 | 0.160 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2010 | 2341 | 0.160 |
Why?
|
| Sarcoma, Myeloid | 1 | 2018 | 95 | 0.160 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2017 | 52 | 0.160 |
Why?
|
| Cohort Studies | 6 | 2022 | 9244 | 0.160 |
Why?
|
| Genes, Neoplasm | 1 | 2019 | 324 | 0.150 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 2843 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 224 | 0.150 |
Why?
|
| GTP Phosphohydrolases | 1 | 2019 | 336 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2019 | 299 | 0.150 |
Why?
|
| Genetic Association Studies | 2 | 2020 | 1084 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2021 | 810 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 15694 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 402 | 0.150 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2020 | 436 | 0.150 |
Why?
|
| Splenomegaly | 1 | 2017 | 158 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 338 | 0.150 |
Why?
|
| Monocytes | 1 | 2021 | 788 | 0.150 |
Why?
|
| Calbindin 2 | 1 | 2016 | 40 | 0.150 |
Why?
|
| Fibrosis | 2 | 2022 | 793 | 0.140 |
Why?
|
| Health Policy | 1 | 2019 | 291 | 0.140 |
Why?
|
| CD5 Antigens | 1 | 2017 | 112 | 0.140 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 235 | 0.140 |
Why?
|
| Follow-Up Studies | 9 | 2023 | 14889 | 0.140 |
Why?
|
| Risk | 1 | 2021 | 1972 | 0.140 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2016 | 67 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2019 | 417 | 0.140 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 984 | 0.140 |
Why?
|
| DNA, Viral | 2 | 2016 | 694 | 0.140 |
Why?
|
| Herpes Simplex | 1 | 2017 | 95 | 0.140 |
Why?
|
| Paraproteins | 1 | 2015 | 39 | 0.140 |
Why?
|
| Risk Factors | 6 | 2020 | 17523 | 0.130 |
Why?
|
| T-Cell Intracellular Antigen-1 | 1 | 2015 | 16 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2021 | 2086 | 0.130 |
Why?
|
| Texas | 3 | 2021 | 6311 | 0.130 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 366 | 0.130 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2015 | 32 | 0.130 |
Why?
|
| Stem Cell Transplantation | 2 | 2021 | 1360 | 0.130 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 237 | 0.130 |
Why?
|
| Vincristine | 4 | 2023 | 1511 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 3203 | 0.130 |
Why?
|
| Castleman Disease | 1 | 2015 | 69 | 0.130 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 1021 | 0.120 |
Why?
|
| CD8 Antigens | 1 | 2015 | 170 | 0.120 |
Why?
|
| Macrophages | 1 | 2021 | 1304 | 0.120 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2014 | 68 | 0.120 |
Why?
|
| Inflammation | 2 | 2022 | 2522 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 1146 | 0.120 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 269 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2021 | 806 | 0.120 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2014 | 60 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 3639 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2017 | 294 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2015 | 181 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2023 | 2488 | 0.120 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 1914 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 332 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 134 | 0.110 |
Why?
|
| Polycythemia Vera | 1 | 2015 | 238 | 0.110 |
Why?
|
| Tumor Burden | 2 | 2021 | 1987 | 0.110 |
Why?
|
| Splicing Factor U2AF | 2 | 2023 | 48 | 0.110 |
Why?
|
| DNA Damage | 1 | 2021 | 1954 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2020 | 2218 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 904 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 1299 | 0.110 |
Why?
|
| Fetal Growth Retardation | 1 | 2014 | 194 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 13658 | 0.110 |
Why?
|
| Exons | 1 | 2016 | 1328 | 0.110 |
Why?
|
| Transplantation Conditioning | 1 | 2021 | 2238 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2017 | 1385 | 0.100 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2023 | 275 | 0.100 |
Why?
|
| Skin | 1 | 2017 | 1259 | 0.100 |
Why?
|
| Cyclophosphamide | 4 | 2023 | 3001 | 0.100 |
Why?
|
| RNA Splicing Factors | 2 | 2023 | 153 | 0.100 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 320 | 0.100 |
Why?
|
| Dasatinib | 1 | 2015 | 862 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1249 | 0.100 |
Why?
|
| Dexamethasone | 3 | 2023 | 1450 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 666 | 0.090 |
Why?
|
| Urine | 1 | 2010 | 143 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 698 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1506 | 0.090 |
Why?
|
| Premenopause | 2 | 2020 | 131 | 0.090 |
Why?
|
| Simian virus 40 | 1 | 2010 | 137 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2014 | 462 | 0.090 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2011 | 303 | 0.090 |
Why?
|
| Cytodiagnosis | 1 | 2010 | 220 | 0.090 |
Why?
|
| Combined Modality Therapy | 5 | 2019 | 8865 | 0.090 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2009 | 96 | 0.090 |
Why?
|
| Testicular Neoplasms | 1 | 2013 | 529 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2014 | 419 | 0.090 |
Why?
|
| Histiocytes | 2 | 2020 | 94 | 0.090 |
Why?
|
| Mammography | 1 | 2015 | 1010 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2019 | 2819 | 0.080 |
Why?
|
| Urothelium | 1 | 2010 | 254 | 0.080 |
Why?
|
| Papillomaviridae | 1 | 2012 | 624 | 0.080 |
Why?
|
| Benzamides | 1 | 2014 | 1832 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2022 | 749 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2018 | 6100 | 0.080 |
Why?
|
| Microglia | 1 | 2009 | 164 | 0.080 |
Why?
|
| Lymphocytes | 2 | 2024 | 1234 | 0.080 |
Why?
|
| Animals | 8 | 2024 | 59536 | 0.080 |
Why?
|
| Workflow | 2 | 2019 | 275 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2016 | 1471 | 0.080 |
Why?
|
| Urinary Bladder | 1 | 2010 | 575 | 0.080 |
Why?
|
| Leukocytes | 1 | 2009 | 422 | 0.080 |
Why?
|
| Mutation Rate | 2 | 2018 | 223 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2022 | 12873 | 0.070 |
Why?
|
| Central Nervous System | 1 | 2009 | 436 | 0.070 |
Why?
|
| Logistic Models | 1 | 2014 | 3441 | 0.070 |
Why?
|
| Vidarabine | 2 | 2022 | 1341 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 607 | 0.070 |
Why?
|
| Swimming | 1 | 2006 | 27 | 0.070 |
Why?
|
| Receptors, Dopamine | 1 | 2006 | 42 | 0.070 |
Why?
|
| Methotrexate | 2 | 2023 | 999 | 0.070 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2009 | 488 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 3981 | 0.070 |
Why?
|
| Formaldehyde | 1 | 2006 | 114 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2016 | 6150 | 0.070 |
Why?
|
| Karyotyping | 2 | 2017 | 1022 | 0.070 |
Why?
|
| Proteomics | 2 | 2023 | 1380 | 0.070 |
Why?
|
| Analgesia | 1 | 2006 | 94 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2023 | 1399 | 0.070 |
Why?
|
| Piperazines | 1 | 2014 | 2101 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2010 | 1620 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2018 | 9180 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4638 | 0.060 |
Why?
|
| Hematoxylin | 1 | 2023 | 34 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 4971 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2012 | 980 | 0.060 |
Why?
|
| Salvage Therapy | 2 | 2023 | 2054 | 0.060 |
Why?
|
| Neurons | 1 | 2014 | 2287 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 6009 | 0.050 |
Why?
|
| Daunorubicin | 1 | 2023 | 301 | 0.050 |
Why?
|
| Immune Evasion | 1 | 2023 | 73 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2023 | 367 | 0.050 |
Why?
|
| Monosomy | 1 | 2022 | 95 | 0.050 |
Why?
|
| Oxazoles | 1 | 2022 | 60 | 0.050 |
Why?
|
| Sclerosis | 1 | 2022 | 84 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2006 | 953 | 0.050 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2021 | 23 | 0.050 |
Why?
|
| Histone Demethylases | 1 | 2023 | 144 | 0.050 |
Why?
|
| Cell Line | 2 | 2020 | 5114 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2024 | 576 | 0.050 |
Why?
|
| Epigenomics | 1 | 2023 | 266 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2022 | 204 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 1742 | 0.050 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2021 | 27 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2014 | 2947 | 0.050 |
Why?
|
| Oncogene Fusion | 1 | 2021 | 63 | 0.050 |
Why?
|
| Child | 5 | 2021 | 29154 | 0.050 |
Why?
|
| Oxides | 1 | 2021 | 211 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2023 | 400 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8873 | 0.050 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2021 | 109 | 0.050 |
Why?
|
| Mice | 5 | 2024 | 34495 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2022 | 314 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 371 | 0.050 |
Why?
|
| Maintenance Chemotherapy | 1 | 2021 | 202 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2021 | 179 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 406 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2021 | 290 | 0.040 |
Why?
|
| Pyridones | 1 | 2022 | 348 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 212 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2022 | 560 | 0.040 |
Why?
|
| Surface Properties | 1 | 2019 | 180 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 577 | 0.040 |
Why?
|
| Staurosporine | 1 | 2019 | 143 | 0.040 |
Why?
|
| Biological Products | 1 | 2022 | 274 | 0.040 |
Why?
|
| Propensity Score | 1 | 2022 | 750 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2006 | 1000 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2024 | 731 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2022 | 524 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2021 | 354 | 0.040 |
Why?
|
| Tretinoin | 1 | 2021 | 623 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 452 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2020 | 16273 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2023 | 803 | 0.040 |
Why?
|
| Diploidy | 1 | 2018 | 114 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2023 | 5270 | 0.040 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2021 | 362 | 0.040 |
Why?
|
| Ki-1 Antigen | 1 | 2019 | 182 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 905 | 0.040 |
Why?
|
| Pyrroles | 1 | 2022 | 576 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 733 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 1290 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 7789 | 0.040 |
Why?
|
| Imidazoles | 1 | 2023 | 999 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 441 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 267 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 470 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2019 | 437 | 0.040 |
Why?
|
| Apoptosis | 2 | 2023 | 7591 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2019 | 574 | 0.040 |
Why?
|
| Janus Kinases | 1 | 2018 | 174 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 1391 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2019 | 749 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2020 | 1113 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2023 | 1048 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2018 | 388 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 672 | 0.030 |
Why?
|
| Aftercare | 1 | 2017 | 259 | 0.030 |
Why?
|
| Paraproteinemias | 1 | 2015 | 61 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2019 | 498 | 0.030 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2015 | 32 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 1516 | 0.030 |
Why?
|
| Pyridines | 1 | 2022 | 1244 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 173 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2020 | 1152 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2019 | 785 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 347 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2015 | 185 | 0.030 |
Why?
|
| Microvessels | 1 | 2016 | 135 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 7702 | 0.030 |
Why?
|
| Etoposide | 1 | 2017 | 870 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2021 | 1026 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 684 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2019 | 884 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 14551 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2016 | 336 | 0.030 |
Why?
|
| Bone Marrow Diseases | 1 | 2015 | 177 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 1121 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2015 | 192 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 2045 | 0.030 |
Why?
|
| Prednisone | 1 | 2017 | 984 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 2139 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 11538 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 137 | 0.030 |
Why?
|
| Computational Biology | 1 | 2020 | 1271 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 833 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 1890 | 0.030 |
Why?
|
| Family | 1 | 2017 | 736 | 0.030 |
Why?
|
| Adenine | 1 | 2016 | 631 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 2483 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2292 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1763 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 3719 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 234 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 615 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 929 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2015 | 410 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2015 | 649 | 0.020 |
Why?
|
| Piperidines | 1 | 2016 | 1035 | 0.020 |
Why?
|
| Gene Expression | 1 | 2019 | 3570 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2015 | 492 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2019 | 1589 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2864 | 0.020 |
Why?
|
| Chemotactic Factors | 1 | 2009 | 42 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 3251 | 0.020 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2009 | 38 | 0.020 |
Why?
|
| Macrophages, Peritoneal | 1 | 2009 | 66 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 1033 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 541 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2009 | 114 | 0.020 |
Why?
|
| Quality of Life | 1 | 2023 | 4532 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 3472 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 1946 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 778 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2330 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 5112 | 0.020 |
Why?
|
| Chemokines | 1 | 2009 | 314 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2009 | 250 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 5159 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 676 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 558 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2009 | 446 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 1320 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 2803 | 0.020 |
Why?
|
| Sulpiride | 1 | 2006 | 8 | 0.020 |
Why?
|
| Dopamine Antagonists | 1 | 2006 | 52 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 650 | 0.020 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2006 | 63 | 0.020 |
Why?
|
| Dopamine Agonists | 1 | 2006 | 85 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2009 | 747 | 0.020 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2006 | 79 | 0.020 |
Why?
|
| Benzazepines | 1 | 2006 | 108 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2009 | 1144 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 3151 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 1538 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2009 | 1271 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 8223 | 0.010 |
Why?
|
| Pregnancy | 1 | 2014 | 7573 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 7551 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 5710 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 6942 | 0.010 |
Why?
|